Close or positive margin after mastectomy and chest wall irradiation
ForT ≤5cm, 0-3 positive nodes, close (≤6mm) or positive deep margin, post-MRM
TL;DR8yr cumulative chest wall recurrence 28% age ≤50 vs 0% age >50 (p=0.04) with close/positive margin, T ≤5cm, 0-3 nodes, no PMRT.
Margin distance itself did not separate risk (≤2mm 24% vs 2.1-6mm 7%, p=0.36); age did, with 28% vs 0% chest wall failure at 8yr. For the PMRT decision in an otherwise low-risk mastectomy pt, this argues for weighting age ≤50 over margin proximity alone, and supports omission in older women with a close margin.
In a woman ≤50 after MRM with T1-T2 disease, 0-3 positive nodes and a deep margin ≤5mm, this supports discussing chest wall RT despite systemic therapy; it does not support PMRT for the margin alone in women >50, where no chest wall failures occurred in 12-13 pts.
Margin distance did not separate chest wall risk (≤2mm 24% vs 2.1-6mm 7%, p=0.36); age ≤50 did (28% vs 0% at 8yr). Supports considering chest wall RT for a close margin in younger women and questions it in women >50 with T ≤5cm and 0-3 nodes.
Gross deep-margin assessment missed 43% of tumors grossly >5mm but <1cm that were microscopically ≤5mm, while gross ≤5mm calls were 90% specific. Microscopic deep-margin assessment changes who is labelled close, and therefore who is referred for PMRT.
11 details
Retrospective single-institution review of 789 mastectomy pts at Fox Chase; 136 (17%) had tumor within 1cm of the deep margin. 34 pts met criteria and received no postoperative RT. Median f/u 59 mo (range 7-143).
Invasive breast cancer, clinical T ≤5cm, 0-3 positive nodes, microscopic deep margin ≤1cm, MRM in all. Median age 43 (29-76); 65% node-negative, 35% 1-3 positive nodes; no deep muscle involvement.
Chemo ± tamoxifen in 23 pts (CMF 12, CAF 10, AC 1); tamoxifen alone in 7. Systemic therapy tracked age: 91% of women ≤50 got chemo vs 25% of women >50.
5 chest wall recurrences, median interval 26 mo. Cumulative incidence 9% at 5yr, 18% at 8yr. Age ≤50 vs >50: 28% vs 0% at 8yr (p=0.04); margin ≤2mm vs 2.1-6mm 24% vs 7% (p=0.36). 5yr OS 82%, DFS 74%.
The source cites Ahlborn (margin ≤4mm 5.7% vs >4mm 3%) and Mentzer (≤5mm 11% vs >5mm 3%), neither significant and both crude rates at short f/u. This series adds the age interaction those did not report.
Age band estimates rest on 11-12 pts per group. 19 of 34 margins were not centrally re-reviewed. Systemic therapy is pre-taxane, pre-HER2-targeted, so absolute risks likely overstate contemporary failure rates.
The title's claim is really two claims: margin alone does not drive risk, and young age does. The first rests on a non-significant comparison in 34 pts, which is absence of evidence rather than evidence of no effect.
Retrospective single-institution series, 5 events; age subgroup confounded with chemo use (91% vs 25%); no RT comparator arm, so PMRT benefit inferred not measured.
- Does young age add chest wall risk independent of grade and systemic therapy?
- Absolute chest wall risk with modern systemic therapy for close margins
- Is PMRT omission safe for close margins in women over 50?
📚 Sources · 📄 1 paper
The longer read
The paper's headline is phrased as a negative (a close or positive margin is not an indication) with a carve-out (except in women 50 or younger), and the two halves deserve different levels of confidence. The carve-out is the positive finding: 28% versus 0% chest wall failure at 8 years, p=0.04. The negative half rests on the observation that margin proximity did not separate risk within the cohort, 24% at ≤2mm versus 7% at 2.1-6mm with p=0.36. That is a large point difference reported as non-significant in a series with five events. Read honestly, margin distance was not shown to matter; it was not shown to be irrelevant either. A reader who takes away "margin doesn't matter" has over-read the data.
The age finding has its own problem, and the authors flag it themselves. Age was tightly coupled to systemic therapy: 91% of women ≤50 received chemotherapy versus 25% of those over 50, and four of the five chest wall failures occurred in chemotherapy-treated patients. With zero events in the older group, no multivariable model can disentangle age from treatment selection or from the biology that prompted chemotherapy in younger women. The authors argue chemotherapy has not been shown to prevent locoregional failure in high-risk mastectomy cohorts, which is a reasonable framing, but the more parsimonious reading is that young age and aggressive features travel together and this series cannot say which carries the risk.
Against the two prior margin series the paper cites, Ahlborn and Mentzer, the direction is consistent: both saw numerically higher local recurrence with close margins, neither significant, both with crude rates over roughly three to four years. Freedman's contribution is longer follow-up with cumulative incidence methods, and the observation that failures accrue late (range out to 127 months), which is exactly why short crude series would underestimate risk. That point about follow-up duration is arguably more durable than the age cutoff itself.
For transfer to current practice, the systemic therapy era matters. Patients received CMF, CAF or AC, without taxanes, HER2-directed therapy or modern endocrine sequencing, and with radiology and pathology standards of the mid-1980s to early 1990s. Contemporary locoregional failure rates after mastectomy are lower across the board, so the 28% figure should be treated as an upper bound for a young, close-margin patient today rather than a working estimate. The relative signal, that younger women carry disproportionate chest wall risk when margins are close, is more likely to survive than the absolute number.
The pathology finding is underappreciated. Gross assessment calling a tumor >5mm but <1cm from the margin missed 43% that were microscopically ≤5mm. If margin status is going to enter a PMRT discussion at all, it has to be a microscopic measurement. What would make this study wrong: a larger contemporary series showing that, after adjusting for grade, receptor status and systemic therapy, young age adds nothing for close-margin, low-nodal-burden disease. Until then, the series is best used as one input that tilts toward chest wall RT in a young woman with a close margin, not as license to omit it in everyone else.